Latest available resultsQuarter ended June 30, 202610-Q · August 6, 2026
Filed with the SECViatris Inc
VTRSPharma & biotech
Next reportNovember 4, 2026Analyst forecast 0.654 $/share
Revenue
$3.76B
▲ +4.9% vs prior year% YoY
Net income
—
EPS
-0.10$
Net margin
—
Revenue▲ +4.9 %
Margins (% of revenue)GrossOperatingNet N/A
Net income
N/ANot reported for the displayed periods
EPS
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $3.76B | |
| Gross profit | $1.46B | 38.8 % |
| Operating income | $6.30M | 0.2 % |
| Net income | — | |
| R&D | $248.30M | 6.6 % |
| EPS (diluted) | -0.10 $ | |
| Balance sheet | ||
| Assets | $35.04B | |
| Liabilities | $20.78B | |
| Equity | $14.26B | |
| Cash | $886.50M | |
| Capital | ||
| Shares outstanding | 1.15B | as of 2026-08-03 |
| Public float | — | |